Introduction and Aims: Treatment of Wilson Disease (WD) with chelating agents such as d-Penicillamine (DPA)
or trientine decreases the pathologic accumulation of copper and removes circulating
non-ceruloplasmin bound copper (NCC). There are no prior controlled studies comparing
DPA with trientine. The study aim is to determine if maintenance therapy for WD with
a novel tetrahydrochloride trientine formulation (TETA4) is safe and effective when
compared to DPA.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Digestive and Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2022 Published by Elsevier Inc.
